Jessica Donington, MD - The Expanding Role of Immunotherapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Thoracic Surgeons - a podcast by PVI, PeerView Institute for Medical Education

Go online to PeerView.com/CPZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New evidence from clinical trials assessing immunotherapies and combinations in lung cancer is emerging at a rapid pace. As a result, the treatment landscape is constantly evolving, and checkpoint inhibitor–based therapeutic approaches are establishing a foothold not only in advanced disease but in earlier stages of lung cancer as well. Immunotherapy has proven to be effective in the context of multimodal therapy in stage III locally advanced NSCLC. This has increased excitement about further expanding the role of this therapeutic approach in earlier stages of lung cancer, including resectable disease. A range of novel single-agent and combination immunotherapeutic approaches are being explored in studies in different settings and populations throughout the disease continuum, and the results are eagerly anticipated. However, many challenges and questions related to the optimal use of immunotherapy in stage III and earlier stages of lung cancer remain. In this activity, based on a recent satellite symposium, an expert panel of two surgeons and a medical oncologist offers practical guidance on how to navigate the rapidly changing and complex immuno-oncology landscape in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, Review the present immunotherapy landscape and state of the science in lung cancer, including key approvals/indications in different settings from early-stage to more advanced disease, Discuss key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, including resectable disease, and available data from such trials, Determine the best treatment approaches for patients with stage III or earlier lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care.

Further episodes of PeerView Immunology

Further podcasts by PVI, PeerView Institute for Medical Education

Website of PVI, PeerView Institute for Medical Education